Adjuvant and neoadjuvant therapy for pancreatic cancer Journal Article


Authors: Li, D.; O'Reilly, E. M.
Article Title: Adjuvant and neoadjuvant therapy for pancreatic cancer
Abstract: Pancreas adenocarcinoma is an aggressive malignancy. The risk of recurrence remains high even for patients with localized disease undergoing surgical resection. Adjuvant systemic therapy has demonstrated the ability to reduce the risk of recurrence and prolong survival. Determination of optimal adjuvant treatment, systemic therapy, and/or combinations to further improve recurrence rates and overall survival are still needed. Neoadjuvant therapy represents an alternative emerging paradigm of investigation with several theoretic advantages over adjuvant therapy. This article summarizes the major adjuvant and neoadjuvant studies for pancreas adenocarcinoma and highlights key areas of ongoing investigation.
Keywords: adjuvant therapy; neoadjuvant therapy; pancreas adenocarcinoma; long-term survival; phase-ii trial; randomized controlled-trial; clinical; trials; ductal adenocarcinoma; plus gemcitabine; secreting tumor vaccine; immune activation; borderline; anti-gal; resectable adenocarcinoma
Journal Title: Surgical Oncology Clinics of North America
Volume: 25
Issue: 2
ISSN: 1055-3207
Publisher: Elsevier Inc.  
Date Published: 2016-04-01
Start Page: 311
End Page: 326
Language: English
ACCESSION: WOS:000374621800008
DOI: 10.1016/j.soc.2015.11.010
PROVIDER: wos
PUBMED: 27013366
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Eileen O'Reilly
    789 O'Reilly
  2. Daneng Li
    8 Li